INTRODUCTION
Cultured insulin-secreting cell lines offer a potential alternative to isolated pancreatic islets for implantation into patients with insulinopenic forms of diabetes mellitus. [2, 8, 18, 2] Indeed, considerable effort has been devoted in the past five years to generation of new glucose-responsive islet cell lines and cellular engineering of existing insulin-secreting cells to confer attributes [7 19 21 29] responsible for glucose sensitivity [8, 25] However, there are important unresolved issues concerning the implantation of insulin-secreting cell lines in vivo, including their containment, control of proliferation, immunological isolation, and responsiveness to glucose. [2, 4, 18, 25] Insulinoma-derived insulin-secreting cell lines generally show limited responsiveness to changes in extracellular glucose concentrations within the physiological range. [11, 14, 18, 19, 21] Electrofusion technology provides a method to produce immortal hybrid cells and this technology has recently been applied to the development of glucose-sensitive insulin-secreting cells. [18, 19] [6, 17, 18, 19, 26] This study has examined the ability of electro- 10% (v/v) foetal calf serum, 100IU/ml penicillin and 0.1mg/ml streptomycin, with 95% air and 5% CO 2 at 37C. The production, culture and functional characterisation of this cell line are described in detail elsewhere. Cells were maintained in 75cm 3 flasks and used at passages (Fig. 1), [17] [18] [19] Consistent with these early studies, BRIN-BD11 cells used in the present experiments showed insulin secretory responses to glucose, Lalanine, tGLP-1 and CCK-8. [1, 17, 22] The therapeutic potential of electrofusionderived insulin-secreting cells has been demonstrated herein by the lowering of plasma glucose concentrations and elimination of the need for exogenous insulin injections after intraperitoneal implantation of BRIN-BD11 cells in severely diabetic insulin-treated nude mice. These observations parallel studies using intact islets, dispersed islet cells or immunoprotected MIN-6-cells, [4'13'15'16' [3, 311 However, the present experimental system might provide an opportunity to identify the full spectrum of factors and target genes involved.
Despite unchanged basal insulin secretion and improved glucose-regulated insulin secretion of BRIN-BD11 cells during in vitro studies at 9 and 20 days after re-section, plasma glucose concentrations of the diabetic nude mice declined to hypoglycaemic levels by [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] days after implantation. This indicates that the capacity of implanted cells to limit insulin secretion in the face of low plasma glucose was insufficient to compensate for the increasing f-cell mass.
Strategies are being developed in other laboratories to offset this problem, for example by incorporating an antibiotic-sensitive inducer gene into surrogate -cells to limit cell growth, [5, 81 and by the use of encapsulation and prosthetic implantation devices. [4, 13, 16, 23] In conclusion, the present study has demonstrated the 
